search
Back to results

Safety and Efficacy of the Cochlear Nucleus CI422 Cochlear Implant in Adults

Primary Purpose

Hearing Loss

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Nucleus CI422 Cochlear Implant with N6 Sound Processor
Sponsored by
Cochlear
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hearing Loss

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Eighteen years of age or older at the time of implantation
  2. Moderate low frequency thresholds up to and including 1000 Hz, severe to profound high frequency (above 3000 Hz) sensorineural hearing loss
  3. Minimum of 30 days experience with appropriately fit bilateral amplification, fit using the standardized National Acoustics Laboratory (NAL) fitting method described in the Fitting and Use of Hearing Aids section below
  4. Aided Consonant Nucleus Consonant (CNC) word recognition score (mean of two lists) between 10% and 50%, inclusive in the ear to be implanted
  5. Aided CNC word recognition score (mean of two lists) in the contralateral ear equal to, or better than, the ear to be implanted but not more than 70%
  6. Willingness to use bimodal stimulation (i.e., a cochlear implant on one ear and a hearing aid on the contralateral ear) through at least 6-months postactivation
  7. English spoken as a primary language

Exclusion Criteria:

  1. Duration of severe-to-profound hearing loss greater than 30 years
  2. Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age)
  3. Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator
  4. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array
  5. Conductive overlay of 15 decibels (dB) or greater at two or more frequencies, in the range 500 to 1000 Hz
  6. Deafness due to lesions of the acoustic nerve or central auditory pathway
  7. Absence of cochlear development
  8. Diagnosis of auditory neuropathy
  9. Active middle-ear infection
  10. Tympanic membrane perforation in the presence of active middle ear disease
  11. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
  12. Unwillingness or inability of the candidate to comply with all investigational requirements as determined by the Investigator
  13. Additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the Investigator

Sites / Locations

  • Greater Baltimore Medical Center
  • University of North Carolina

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Nucleus CI422 Cochlear Implant with Nucleus 6 (N6) Sound Processor

Arm Description

Outcomes

Primary Outcome Measures

Change in Open Set Monosyllabic Word Recognition Score as Measured on a Consonant Nucleus Consonant (CNC) Word Test
Performance at 6 months postactivation compared to pre-operative word recognition score (percent correct: 0-100%, where a 0% is the lowest score and a 100% is the highest score)

Secondary Outcome Measures

Full Information

First Posted
May 29, 2013
Last Updated
January 5, 2021
Sponsor
Cochlear
search

1. Study Identification

Unique Protocol Identification Number
NCT01867008
Brief Title
Safety and Efficacy of the Cochlear Nucleus CI422 Cochlear Implant in Adults
Official Title
Safety and Efficacy of the Cochlear Nucleus CI422 Cochlear Implant in Adults
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
November 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cochlear

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Clinical study to evaluate the safety and efficacy of the Cochlear™ Nucleus® CI422 cochlear implant for new cochlear implant adult recipients with broader requirements to be considered an eligible candidate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hearing Loss

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
55 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nucleus CI422 Cochlear Implant with Nucleus 6 (N6) Sound Processor
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Nucleus CI422 Cochlear Implant with N6 Sound Processor
Primary Outcome Measure Information:
Title
Change in Open Set Monosyllabic Word Recognition Score as Measured on a Consonant Nucleus Consonant (CNC) Word Test
Description
Performance at 6 months postactivation compared to pre-operative word recognition score (percent correct: 0-100%, where a 0% is the lowest score and a 100% is the highest score)
Time Frame
Preoperative baseline to 6 months postactivation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eighteen years of age or older at the time of implantation Moderate low frequency thresholds up to and including 1000 Hz, severe to profound high frequency (above 3000 Hz) sensorineural hearing loss Minimum of 30 days experience with appropriately fit bilateral amplification, fit using the standardized National Acoustics Laboratory (NAL) fitting method described in the Fitting and Use of Hearing Aids section below Aided Consonant Nucleus Consonant (CNC) word recognition score (mean of two lists) between 10% and 50%, inclusive in the ear to be implanted Aided CNC word recognition score (mean of two lists) in the contralateral ear equal to, or better than, the ear to be implanted but not more than 70% Willingness to use bimodal stimulation (i.e., a cochlear implant on one ear and a hearing aid on the contralateral ear) through at least 6-months postactivation English spoken as a primary language Exclusion Criteria: Duration of severe-to-profound hearing loss greater than 30 years Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age) Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array Conductive overlay of 15 decibels (dB) or greater at two or more frequencies, in the range 500 to 1000 Hz Deafness due to lesions of the acoustic nerve or central auditory pathway Absence of cochlear development Diagnosis of auditory neuropathy Active middle-ear infection Tympanic membrane perforation in the presence of active middle ear disease Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator Unwillingness or inability of the candidate to comply with all investigational requirements as determined by the Investigator Additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the Investigator
Facility Information:
Facility Name
Greater Baltimore Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27517
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of the Cochlear Nucleus CI422 Cochlear Implant in Adults

We'll reach out to this number within 24 hrs